Provider-ship:
This activity is jointly provided Medical Education Resources, Inc., a non-profit medical education company, and the Dermatology Research and Education Foundation.
Target Audience
This conference has been designed for dermatologists, dermatology residents, primary care physicians, physicians involved in the care of patients with skin diseases, dermatology PAs, and dermatology nurse practitioners.
Education Grant:
This activity is supported by educational grants from Incyte, Galderma Laboratories, Janssen Biotech and Novartis Pharmaceuticals Corporation.
Learning Objectives
At the conclusion of this course, you will be able to:
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and the Dermatology Research and Education Foundation (DREF). MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 15 Interprofessional continuing Education (IPCE) credit for learning and change
Physician Credit
Medical Education Resources designates this live activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
Medical Education Resources designates this live activity for a maximum of 15 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 15 contact hours.
Disclosure of Conflicts of Interest
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported conflicts of interest are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Jashin J. Wu, MD
Grants/Research Support: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer
Consulting Fees: Lilly, EPI Health, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, and Zerigo Health
Speakers’ Bureau: AbbVie, Amgen, Bausch Health, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB
Neal Bhatia, MD
Grants/Research Support: Abbvie, Almirall, Arcutis, Arena, Biofrontera, BMS, BI, Brickell, Castle, Dermavant, EPI Health/MC2/Novan, Ferndale, Galderma, Genentech, InCyte, ISDIN, J&J, LaRoche-Posay, Leo, Lilly, Novartis, Ortho, Pfizer, P&G, Regeneron, Sanofi, Stemline, SunPharma, and Verrica
Consulting Fees: Abbvie, Almirall, Arcutis, Arena, Biofrontera, BMS, BI, Brickell, Castle, Dermavant, EPI Health/MC2/Novan, Ferndale, Galderma, Genentech, InCyte, ISDIN, J&J, LaRoche-Posay, Leo, Lilly, Novartis, Ortho, Pfizer, P&G, Regeneron, Sanofi, Stemline, SunPharma, and Verrica
Speakers’ Bureau: Abbvie, Almirall, Arcutis, Arena, Biofrontera, BMS, BI, Brickell, Castle, Dermavant, EPI Health/MC2/Novan, Ferndale, Galderma, Genentech, InCyte, ISDIN, J&J, LaRoche-Posay, Leo, Lilly, Novartis, Ortho, Pfizer, P&G, Regeneron, Sanofi, Stemline, SunPharma, and Verrica
Andy Blauvelt, MD
Grants/Research Support: Abbvie, Arcutis, Bristol-Myers Squibbs, Eli Lilly and Company, Pfizer, Regeneron, Sanofi, UCB
Consulting Fees: Abbvie, Abcentra, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boeheringer Ingelheim, BMS, Cara Therapeutics, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, Genentech, HighlightII Pharma, InCyte, InnoventBio, Janssen, Landos, Leo, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB Pharma, Vibliome, Xencor LaRoche-Posay, Leo, Lilly, Novartis, Ortho, Pfizer, P&G, Regeneron, Sanofi, Stemline, SunPharma, and Verrica
Speakers’ Bureau: Abbvie, Arcutis, Bristol-Myers Squibbs, Eli Lilly and Company, Pfizer, Regeneron, Sanofi, UCB
Ashley Crew, MD
Nothing to disclose.
Dawn Eichenfield, MD
Grants/Research Support: La Roche Posay North America
Consulting Fees: Beiersdorf
Benjamin Kelley, MD
Nothing to disclose.
John Koo, MD
Consulting Fees and Speakers’ Bureau: Abbvie, Amgen, Janssen, UCB, Regeneron, Sanofi Genzyme, EPI, Eli-Lilly
Krystal Mitchell, MD
Nothing to disclose.
Ron Moy, MD
Ownership Interest: CellularMD
Arisa Ortiz, MD
Grants/Research Support: Revance
Consulting Fees: Aerolase, Bausch Health, Endo, Galderma, Rodan + Fields, Sciton, R2, Alastin, Cutera, BTL, Procter & Gamble
Speakers’ Bureau: Allergan, Sofwave
Veronica Shi, MD
Nothing to disclose.
Seaver Soon, MD
Consulting Fees: La Roche Posay
Speakers’ Bureau: Revance, Merz
Diana Wang, MD
Nothing to disclose.
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Planners at Dermatology Research and Education Foundation
No financial relationships to disclose
Planners at Medical Education Resources
No financial relationships to disclose
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources and the Dermatology Research and Education Foundation. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
This activity is jointly provided Medical Education Resources, Inc., a non-profit medical education company, and the Dermatology Research and Education Foundation.
Target Audience
This conference has been designed for dermatologists, dermatology residents, primary care physicians, physicians involved in the care of patients with skin diseases, dermatology PAs, and dermatology nurse practitioners.
Education Grant:
This activity is supported by educational grants from Incyte, Galderma Laboratories, Janssen Biotech and Novartis Pharmaceuticals Corporation.
Learning Objectives
At the conclusion of this course, you will be able to:
- Discuss the new treatments for psoriasis and how to choose between them.
- Evaluate older and newer therapies for atopic dermatitis.
- Discern various options for managing skin cancer and actinic keratoses.
- Assess the various therapies available for acne.
- Describe infectious diseases of the skin and management of these conditions.
- Discuss therapeutic options for disorders of pigment, hair, and nails.
- Identify optimal patients for aesthetic procedures such as botulinum, fillers, chemical peels, and lasers.
- Describe concepts learned that can be incorporated directly into clinical practice.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and the Dermatology Research and Education Foundation (DREF). MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 15 Interprofessional continuing Education (IPCE) credit for learning and change
Physician Credit
Medical Education Resources designates this live activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
Medical Education Resources designates this live activity for a maximum of 15 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 15 contact hours.
Disclosure of Conflicts of Interest
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported conflicts of interest are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Jashin J. Wu, MD
Grants/Research Support: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer
Consulting Fees: Lilly, EPI Health, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, and Zerigo Health
Speakers’ Bureau: AbbVie, Amgen, Bausch Health, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB
Neal Bhatia, MD
Grants/Research Support: Abbvie, Almirall, Arcutis, Arena, Biofrontera, BMS, BI, Brickell, Castle, Dermavant, EPI Health/MC2/Novan, Ferndale, Galderma, Genentech, InCyte, ISDIN, J&J, LaRoche-Posay, Leo, Lilly, Novartis, Ortho, Pfizer, P&G, Regeneron, Sanofi, Stemline, SunPharma, and Verrica
Consulting Fees: Abbvie, Almirall, Arcutis, Arena, Biofrontera, BMS, BI, Brickell, Castle, Dermavant, EPI Health/MC2/Novan, Ferndale, Galderma, Genentech, InCyte, ISDIN, J&J, LaRoche-Posay, Leo, Lilly, Novartis, Ortho, Pfizer, P&G, Regeneron, Sanofi, Stemline, SunPharma, and Verrica
Speakers’ Bureau: Abbvie, Almirall, Arcutis, Arena, Biofrontera, BMS, BI, Brickell, Castle, Dermavant, EPI Health/MC2/Novan, Ferndale, Galderma, Genentech, InCyte, ISDIN, J&J, LaRoche-Posay, Leo, Lilly, Novartis, Ortho, Pfizer, P&G, Regeneron, Sanofi, Stemline, SunPharma, and Verrica
Andy Blauvelt, MD
Grants/Research Support: Abbvie, Arcutis, Bristol-Myers Squibbs, Eli Lilly and Company, Pfizer, Regeneron, Sanofi, UCB
Consulting Fees: Abbvie, Abcentra, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boeheringer Ingelheim, BMS, Cara Therapeutics, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, Genentech, HighlightII Pharma, InCyte, InnoventBio, Janssen, Landos, Leo, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB Pharma, Vibliome, Xencor LaRoche-Posay, Leo, Lilly, Novartis, Ortho, Pfizer, P&G, Regeneron, Sanofi, Stemline, SunPharma, and Verrica
Speakers’ Bureau: Abbvie, Arcutis, Bristol-Myers Squibbs, Eli Lilly and Company, Pfizer, Regeneron, Sanofi, UCB
Ashley Crew, MD
Nothing to disclose.
Dawn Eichenfield, MD
Grants/Research Support: La Roche Posay North America
Consulting Fees: Beiersdorf
Benjamin Kelley, MD
Nothing to disclose.
John Koo, MD
Consulting Fees and Speakers’ Bureau: Abbvie, Amgen, Janssen, UCB, Regeneron, Sanofi Genzyme, EPI, Eli-Lilly
Krystal Mitchell, MD
Nothing to disclose.
Ron Moy, MD
Ownership Interest: CellularMD
Arisa Ortiz, MD
Grants/Research Support: Revance
Consulting Fees: Aerolase, Bausch Health, Endo, Galderma, Rodan + Fields, Sciton, R2, Alastin, Cutera, BTL, Procter & Gamble
Speakers’ Bureau: Allergan, Sofwave
Veronica Shi, MD
Nothing to disclose.
Seaver Soon, MD
Consulting Fees: La Roche Posay
Speakers’ Bureau: Revance, Merz
Diana Wang, MD
Nothing to disclose.
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Planners at Dermatology Research and Education Foundation
No financial relationships to disclose
Planners at Medical Education Resources
No financial relationships to disclose
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources and the Dermatology Research and Education Foundation. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
|
|
